Use of 2,5-Dihydroxybenzenesulfonic Acid in the Manufacturing of Medicines, Applicable to the Treatment of Angiodependent Diseases

Abstract

Provided is the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, described is the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. Also described is the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, described is the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. Additionally, the therapeutic efficacy of said compounds, based on the combined anti proliferative, antiangiogenic and proapaptotic capacities thereof, in the treatment of chronic psoriatic plaques is provided.

What is claimed is: 
     
         1 . A method of treating an angiodependent disease, comprising administering 2,5-dihydroxybenzenesulfonic acid, or a salt thereof with a pharmaceutically acceptable inorganic or organic acid or base. 
     
     
         2 . The method of  claim 1 , wherein a salt of 2,5-dihydroxybenzenesulfonic acid with an inorganic or organic base is administered. 
     
     
         3 . The method of  claim 1 , wherein a salt of 2,5-dihydroxybenzenesulfonic acid with an inorganic base is administered. 
     
     
         4 . The method of  claim 1 , wherein a potassium, calcium, or magnesium salt of 2,5-dihydroxybenzenesulfonic acid is administered. 
     
     
         5 . The method of  claim 1 , further comprising administering a cytostatic medicine. 
     
     
         6 . The method of  claim 1 , wherein an angiodependent disease is psoriasis. 
     
     
         7 . The method of  claim 1 , wherein 2,5-dihydroxybenzenesulfonic acid or a salt is administered systemically. 
     
     
         8 . The method of  claim 1 , wherein 2,5-dihydroxybenzenesulfonic acid or a salt is administered topically. 
     
     
         9 . A method of reducing psoriasis hyperkeratosis, comprising administering 2,5-dihydroxybenzenesulfonic acid, or a salt thereof with a pharmaceutically acceptable inorganic or organic acid or base. 
     
     
         10 . The method of  claim 9 , wherein 2,5-dihydroxybenzenesulfonic acid or a salt is administered topically. 
     
     
         11 . The method of  claim 9 , wherein a salt of 2,5-dihydroxybenzenesulfonic acid with an inorganic or organic base is administered. 
     
     
         12 . The method of  claim 9 , wherein a salt of 2,5-dihydroxybenzenesulfonic acid with an inorganic base is administered. 
     
     
         13 . The method of  claim 9 , wherein a salt of 2,5-dihydroxybenzenesulfonic acid with an inorganic base is administered topically. 
     
     
         14 . The method of  claim 9 , wherein a potassium, calcium, or magnesium salt of 2,5-dihydroxybenzenesulfonic acid is administered. 
     
     
         15 . A method of reducing psoriasis hyperkeratosis, comprising topically administering a potassium, calcium, or magnesium salt of 2,5-dihydroxybenzenesulfonic acid.